Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeted therapy for cancer

Targeted therapy for cancer The recent approval in the US and Europe of imatinib (Gleevac™) for patients with bcr/abl-positive chronic myelogenous leukemia and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment are driving a new era of integrated diagnostics and therapeutics. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Targeted therapy for cancer

American Journal of Cancer , Volume 3 (4) – Aug 10, 2012

Loading next page...
 
/lp/springer-journals/targeted-therapy-for-cancer-0bRy8RdmNB
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403040-00001
Publisher site
See Article on Publisher Site

Abstract

The recent approval in the US and Europe of imatinib (Gleevac™) for patients with bcr/abl-positive chronic myelogenous leukemia and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment are driving a new era of integrated diagnostics and therapeutics.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References